Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc.

Kodiak Sciences is a biopharmaceutical company researching, developing and commercializing therapeutics for retinal diseases.

Kodiak Sciences

Kodiak Sciences | 9,017 followers on LinkedIn. We are a clinical stage biopharma company bringing new science to prevent and treat high prevalence retinal diseases. | Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak&#39;s discovery engine.

CEO at Xencor

Bassil Dahiyat

Jean Drouin

Gayathrie Janakiraman

Kim Williams

We look forward to participating in a presentation and panel at #InnovateRetina2024 today. See below for details and we look forward to seeing you there! Slides of the presentation will be made available at the beginning of the presentation here: https://lnkd.in/g-w8vFD4

Join us at 10:30am ET today for our Investor R&D Day! The event can be accessed virtually at: https://lnkd.in/gS2_MUKz

We look forward to hosting our Investor R&D Day on Monday, September 23 at 10:30am ET! “We look forward to addressing the most common questions we’ve received from investors about Kodiak today and sharing how we believe our learnings, our course corrections, and our rapid execution will help us move forward,” said Dr. Victor Perlroth, M.D., Chief Executive Officer. Register here for the webcast: https://lnkd.in/gmCRNV28 For more details see our press release: https://lnkd.in/gjfKXc63

Join us tomorrow at 8am ET at the Goldman Sachs 45th Annual Global Healthcare conference. We look forward to providing an update on our tarcocimab tedromer, KSI-501 and KSI-101 clinical programs. A live webcast of the presentation will be available here: https://lnkd.in/evfm2VPr

On June 8, we look forward to presenting important updates on our late-phase clinical program in retina at this year’s Clinical Trials at the Summit meeting. To all those attending, we hope to see you there!

Today is #ClinicalTrialsDay and in honor of all the investigators and participants in our clinical trials and in others, we want to say thank you! We admire and recognize all that you have done to advance vision care around the world. Learn more about CTD2024 by the Association of Clinical Research Professionals (ACRP) here: https://lnkd.in/e9r9k5Wu

We continue to progress our late- and early-phase retina pipeline programs. Learn more in our latest press release: https://lnkd.in/emWeNWr3

We recently reported fourth quarter and full year 2023 financial results and highlighted important updates about our three clinical programs. Read the full press release here: https://lnkd.in/gm7gZmgQ

We look forward to kicking off the new year by sharing an update on Kodiak’s clinical pipeline in retina at the 42nd Annual J.P. Morgan Healthcare Conference. Tune in tomorrow at 10:30 am ET. A live webcast of the presentation will be available here: https://lnkd.in/g3MyHiVB

We look forward to speaking today at the 6th annual Evercore ISI HealthCONx conference! Tune into the live webcast at 3:25pm EST to learn more about Kodiak’s latest developments: https://lnkd.in/g-w8vFD4

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue								25.95M -
gross profit								-25.95M -
selling and marketing expenses
general and administrative expenses	3.10M -	3.50M 12.94%	7.58M 116.66%	11.68M 54.12%	28.62M 144.93%	49.71M 73.71%	73.79M 48.43%
selling general and administrative expenses	3.10M -	3.50M 12.94%	7.58M 116.66%	11.68M 54.12%	28.62M 144.93%	49.71M 73.71%	73.79M 48.43%	45.08M 38.91%
research and development expenses	14.05M -	22.02M 56.71%	18.79M 14.66%	37.51M 99.57%	107.39M 186.32%	217.34M 102.39%	267.59M 23.12%	206.30M 22.91%
other expenses	25K -	-1.23M 5,020%	-4.07M 230.98%	265K 106.51%	34K 87.17%	-215K 732.35%	503K 333.95%
cost and expenses	17.15M -	25.52M 48.80%	26.37M 3.34%	49.19M 86.51%	136.01M 176.49%	267.05M 96.35%	341.38M 27.83%	277.32M 18.76%
operating expenses	17.15M -	25.52M 48.80%	26.37M 3.34%	49.19M 86.51%	136.01M 176.49%	267.05M 96.35%	341.38M 27.83%	251.37M 26.37%
interest expense	6K -	1.19M 19,650%	5.52M 365.74%	8K 99.86%	25K 212.50%	22K 12%	18K 18.18%	13K 27.78%
ebitda	-16.87M -	-26.20M 55.33%	-30.45M 16.19%	-47.36M 55.55%	-133.07M 181.00%	-266.97M 100.62%	-333.81M 25.04%	-251.37M 24.69%
operating income	-17.15M -	-25.52M 48.80%	-26.37M 3.34%	-49.19M 86.51%	-136.01M 176.49%	-267.05M 96.35%	-341.38M 27.83%	-277.32M 18.76%
depreciation and amortization	257K -	549K 113.62%	490K 10.75%	1.83M 274.08%	2.94M 60.17%	83K 97.17%	7.57M 9,025.30%	25.95M 242.58%
total other income expenses net	25K -	-1.23M 5,020%	-9.55M 676.42%	1.82M 119.11%	2.91M 59.51%	61K 97.90%	7.56M 12,286.89%	16.83M 122.74%
income before tax	-17.13M -	-27.94M 63.06%	-41.44M 48.35%	-47.37M 14.29%	-133.10M 181.00%	-266.99M 100.60%	-333.82M 25.03%	-260.49M 21.97%
income tax expense	31K -	-45K 245.16%	-9.55M 21,122.22%	-638K 93.32%	-4.15M 550.31%	-8.90M 114.61%	-340.07B 3,819,217.16%
net income	-17.13M -	-27.94M 63.06%	-41.44M 48.35%	-46.73M 12.75%	-128.95M 175.96%	-258.09M 100.15%	339.74B 131,737.58%	-260.49M 100.08%
weighted average shs out	26.56M -	26.56M 0%	14.98M 43.60%	37.85M 152.75%	45.74M 20.84%	51.79M 13.22%	52.25M 0.89%	52.41M 0.32%
weighted average shs out dil	26.56M -	26.56M 0%	14.98M 43.60%	37.85M 152.75%	45.74M 20.84%	51.79M 13.22%	52.25M 0.89%	52.41M 0.32%
eps	-0.65 -	-1.05 61.54%	-2.77 163.81%	-1.23 55.60%	-2.82 129.27%	-4.98 76.60%	6.50K 130,666.47%	-4.97 100.08%
epsdiluted	-0.65 -	-1.05 61.54%	-2.77 163.81%	-1.23 55.60%	-2.82 129.27%	-4.98 76.60%	6.50K 130,666.47%	-4.97 100.08%

COM:KODIAK

Kodiak Sciences

Last Close

5.90

22/11 21:00

Market Cap

132.39M

Beta: -

Volume Today

251.42K

Avg: -

Preview